Serum Institute is owned by the Indian billionaire Cyrus Poonawalla, is planning to make the vaccine at its two manufacturing plants in India. Over roughly the next five months, Serum will spend some 30 Cr to 40 Cr rupees on making around 3-5 lakh doses per month.
The serum also shares its partnership with the U.S. biotech firm Codagenix and Austria’s Themis on two other COVID-19 vaccine candidates.
The success vaccination remains the Oxford vaccine, called “ChAdOx1 nCoV-19″, which is yet to be proven to work against COVID-19 but it had shown success in animal trials and had progressed to tests on humans.
Poonawalla said he trials of the Oxford vaccine may finish in September but the situation will remain quite stressful as it will ascertain not only whether the vaccine worked but that it induced good immune responses and no unacceptable side effects.
He also assured “a majority of the vaccine, at least initially, would have to go to our countrymen before it goes abroad,” adding that Serum would leave it to the Indian government to decide which countries would get how much of the vaccine and when. He also claimed that Prime Minister Narendra Modi’s office is “very closely” involved in the vaccine production.